September 4, 2019

Ilan Ganot
Chief Executive Officer
Solid Biosciences Inc.
141 Portland Street, Fifth Floor
Cambridge, MA 02139

       Re: Solid Biosciences Inc.
           Registration Statement on Form S-3
           Filed September 3, 2019
           File No. 333-233594

Dear Mr. Ganot:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3

General

1.     We note that the forum selection provisions in your certificate of
incorporation and
       bylaws identify the Court of Chancery of the State of Delaware as the
exclusive forum for
       certain litigation, including any "derivative action." Please disclose
whether
       these provisions apply to actions arising under the Securities Act or
Exchange Act. In that
       regard, we note that Section 27 of the Exchange Act creates exclusive
federal jurisdiction
       over all suits brought to enforce any duty or liability created by the
Exchange Act or the
       rules and regulations thereunder, and Section 22 of the Securities Act
creates concurrent
       jurisdiction for federal and state courts over all suits brought to
enforce any duty or
       liability created by the Securities Act or the rules and regulations
thereunder. If the
       provisions apply to Securities Act claims, please also revise your
prospectus to state that
 Ilan Ganot
Solid Biosciences Inc.
September 4, 2019
Page 2
         there is uncertainty as to whether a court would enforce such
provision and that investors
         cannot waive compliance with the federal securities laws and the rules
and regulations
         thereunder. If this provision does not apply to actions arising under
the Securities Act or
         Exchange Act, please tell us how you will inform investors in future
filings that the
         provision does not apply to any actions arising under the Securities
Act or Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

      Please contact Sonia Bednarowski at 202-551-3666 or Dietrich King at
202-551-
8071 with any questions.



FirstName LastNameIlan Ganot                                   Sincerely,
Comapany NameSolid Biosciences Inc.
                                                               Division of
Corporation Finance
September 4, 2019 Page 2                                       Office of
Healthcare & Insurance
FirstName LastName